Affiliation:
1. Department of Physical Education, Universidade Federal do Maranhão, São Luís, MA, Brazil
2. Universidade Ceuma, São Luís, MA, Brazil
Abstract
Background:
Pulmonary Arterial Hypertension (PAH) is a severe and progressive disease
of pulmonary arterioles. This pathology is characterized by elevation of the pulmonary vascular
resistance and pulmonary arterial pressure, leading to right heart failure and death. Studies have
demonstrated that resveratrol possesses a protective effect on the mechanisms related to the genesis
of the PAH-induced by different models.
Objective:
This study aimed to investigate the dose-related effects of resveratrol in different models
of pulmonary arterial hypertension.
Methods:
To identify eligible papers, we performed a systematic literature search on Scielo, Pub-
Med, and Scholar Google. The research was limited to articles written in English in the last 10
years. We used the following descriptors to search: Pulmonary Arterial Hypertension and Resveratrol,
OR Resveratrol, and Animal models of Pulmonary Arterial Hypertension, OR Resveratrol, and
in vitro models of Pulmonary Arterial Hypertension.
Results:
1724 studies were identified through the descriptors used, fifty-five studies with different
models of pulmonary arterial hypertension were selected for the full review, forty-four were excluded
after application of exclusion and inclusion criteria, totalizing eleven studies included in this
systematic review.
Conclusion:
The results showed that resveratrol, at low and high doses, protects in a dosedependent
manner against the development of PAH induced through monocrotaline, normoxia and
hypoxia models. In addition to having chemopreventive, anti-inflammatory, antioxidant and antiproliferative
properties. In the case of PAH-related myocardial injury, resveratrol protects cells
from apoptosis, thus working as an antiapoptotic agent.
Publisher
Bentham Science Publishers Ltd.
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Reference55 articles.
1. Boucly A.; Weatherald J.; Savale L.; Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017,50(2)
2. Farber H.W.; Loscalzo J.; Pulmonary arterial hypertension. N Engl J Med 2004,351(16),1655-1665
3. Jayasekera G.; Crowe T.; Mackenzie A.; Left atrial function by cardiac MRI in idiopathic pulmonary arterial hypertension (IPAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).C106 Money don’t matter tonight: pulmonary hypertension assessment, prognostication, and treatment. Am Thorac Soc 2017,195,A6903-A3
4. Hoeper M.M.; Galiè N.; Letter by Hoeper and Galie regarding article, “Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: Phase II results from the pulmonary artery denervation-1 study. Circ Cardiovasc Interv 2016,9(1)
5. Paffett M.L.; Hesterman J.; Candelaria G.; Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension. PLoS One 2012,7(7)
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献